• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯乙醇胺四氢萘对肠道运动的体外抑制作用:大鼠结肠中非典型β-肾上腺素能受体的证据

In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon.

作者信息

Bianchetti A, Manara L

机构信息

Research Center Sanofi-Midy S.p.A., Milan, Italy.

出版信息

Br J Pharmacol. 1990 Aug;100(4):831-9. doi: 10.1111/j.1476-5381.1990.tb14100.x.

DOI:10.1111/j.1476-5381.1990.tb14100.x
PMID:1976401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1917598/
Abstract
  1. The new compounds phenylethanolaminotetralines (PEAT), unlike the reference beta-adrenoceptor agonists isoprenaline (Iso), ritodrine (Ri) and salbutamol (Sal), produced half-maximal inhibition of spontaneous motility of rat isolated proximal colon at substantially lower concentrations (EC50 2.7-30 nM) than those inducing beta 2-adrenoceptor-mediated responses (relaxation of guinea-pig isolated trachea and rat uterus) and had virtually no chronotropic action (EC50 greater than 3 x 10(5) M) on the guinea-pig isolated atrium (a beta 1-adrenoceptor-mediated response). 2. The nonselective beta-adrenoceptor antagonists alprenolol and propranolol prevented the inhibition of rat colon motility by the PEAT with low and different potencies (pA2 values around 7.5 and 6.5 respectively). Conversely alprenolol and propranolol had a higher and similar potency (pA2 values around 9.0) in preventing typical beta 1 or beta 2-responses (increase in atrial frequency by Iso or tracheal relaxation by Ri or Sal). 3. The selective beta-adrenoceptor antagonists CGP 20712A (beta 1) and ICI 118,551 (beta 2) either alone or in combination, did not prevent rat colon motility inhibition by the representative PEAT SR 58611A, which was also fully resistant to alpha-adrenoceptor, acetylcholine, dopamine, histamine, opioid and 5-hydroxytryptamine antagonists. 4. These results indicate that the PEAT are a new class of beta-adrenoceptor agonists and suggest that their preferential intestinal action may be accounted for by selectivity for atypical beta-adrenoceptors, abundant in the rat colon and distinct from the currently recognized beta 1 and beta 2 subtypes.
摘要
  1. 新型化合物苯乙醇胺四氢萘(PEAT)与参比β-肾上腺素能受体激动剂异丙肾上腺素(Iso)、利托君(Ri)和沙丁胺醇(Sal)不同,在比诱导β₂-肾上腺素能受体介导反应(豚鼠离体气管和大鼠子宫舒张)低得多的浓度(EC₅₀ 2.7 - 30 nM)下就能产生大鼠离体近端结肠自发运动的半数最大抑制,并且对豚鼠离体心房(一种β₁-肾上腺素能受体介导反应)几乎没有变时作用(EC₅₀大于3×10⁵ M)。2. 非选择性β-肾上腺素能受体拮抗剂阿普洛尔和普萘洛尔能以低且不同的效能(pA₂值分别约为7.5和6.5)阻止PEAT对大鼠结肠运动的抑制。相反,阿普洛尔和普萘洛尔在阻止典型的β₁或β₂反应(Iso引起的心房频率增加或Ri或Sal引起的气管舒张)时具有较高且相似的效能(pA₂值约为9.0)。3. 选择性β-肾上腺素能受体拮抗剂CGP 20712A(β₁)和ICI 118,551(β₂)单独或联合使用,均不能阻止代表性的PEAT SR 58611A对大鼠结肠运动的抑制,该化合物对α-肾上腺素能受体、乙酰胆碱、多巴胺、组胺、阿片类药物和5-羟色胺拮抗剂也完全耐药。4. 这些结果表明,PEAT是一类新型的β-肾上腺素能受体激动剂,并提示它们对肠道的优先作用可能是由于对大鼠结肠中丰富且不同于目前公认的β₁和β₂亚型的非典型β-肾上腺素能受体具有选择性。

相似文献

1
In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon.苯乙醇胺四氢萘对肠道运动的体外抑制作用:大鼠结肠中非典型β-肾上腺素能受体的证据
Br J Pharmacol. 1990 Aug;100(4):831-9. doi: 10.1111/j.1476-5381.1990.tb14100.x.
2
Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins.通过首个β3选择性拮抗剂芳氧基丙醇胺四氢萘对大鼠非典型β肾上腺素能受体进行功能鉴定。
Br J Pharmacol. 1996 Feb;117(3):435-442. doi: 10.1111/j.1476-5381.1996.tb15209.x.
3
Functional evidence for the presence of beta 3-adrenoceptors in the guinea pig common bile duct and colon.豚鼠胆总管和结肠中存在β3 - 肾上腺素能受体的功能证据。
Pharmacology. 1995 Nov;51(5):288-97. doi: 10.1159/000139338.
4
Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors.SR 58611A对犬结肠运动的抑制作用:β3肾上腺素能受体作用的证据
Br J Pharmacol. 1995 Apr;114(7):1447-53. doi: 10.1111/j.1476-5381.1995.tb13368.x.
5
Similar atypical beta-adrenergic receptors mediate in vitro rat adipocyte lipolysis and colonic motility inhibition.相似的非典型β-肾上腺素能受体介导体外大鼠脂肪细胞的脂肪分解和结肠运动抑制。
Life Sci. 1993;53(18):PL297-302. doi: 10.1016/0024-3205(93)90590-y.
6
Inhibition of rat colon motility by stimulation of atypical beta-adrenoceptors with new gut-specific agents.用新型肠道特异性药物刺激非典型β-肾上腺素能受体对大鼠结肠运动的抑制作用。
Pharmacol Res Commun. 1988 Feb;20(2):147-51. doi: 10.1016/s0031-6989(88)80007-9.
7
In vitro inhibition of human colonic motility with SR 59119A and SR 59104A: evidence of a beta3-adrenoceptor-mediated effect.SR 59119A和SR 59104A对人结肠运动的体外抑制作用:β3肾上腺素能受体介导效应的证据
Eur J Pharmacol. 1998 Jul 24;353(2-3):281-7. doi: 10.1016/s0014-2999(98)00419-1.
8
Beta 3-adrenoceptor agonists, BRL 37344 and SR 58611A, do not induce relaxation of human, sheep and guinea-pig airway smooth muscle in vitro.β3肾上腺素能受体激动剂BRL 37344和SR 58611A在体外不能诱导人、绵羊和豚鼠气道平滑肌舒张。
Eur Respir J. 1994 Sep;7(9):1610-5. doi: 10.1183/09031936.94.07091610.
9
Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum.ICI D7114(一种推测的棕色脂肪细胞刺激剂)对组胺收缩的豚鼠回肠的作用评估。
Br J Pharmacol. 1993 Aug;109(4):1212-8. doi: 10.1111/j.1476-5381.1993.tb13751.x.
10
Effects of two beta 3-adrenoceptor agonists, SR 58611A and BRL 37344, and of salbutamol on cholinergic and NANC neural contraction in guinea-pig main bronchi in vitro.两种β3 -肾上腺素能受体激动剂SR 58611A和BRL 37344以及沙丁胺醇对豚鼠离体主支气管胆碱能和非肾上腺素能非胆碱能神经收缩的影响。
Br J Pharmacol. 1993 Dec;110(4):1311-6. doi: 10.1111/j.1476-5381.1993.tb13961.x.

引用本文的文献

1
The β-Adrenergic Receptor: Structure, Physiopathology of Disease, and Emerging Therapeutic Potential.β-肾上腺素能受体:结构、疾病的病理生理学及新兴治疗潜力
Adv Pharmacol Pharm Sci. 2024 Nov 28;2024:2005589. doi: 10.1155/2024/2005589. eCollection 2024.
2
Is the β-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?β-肾上腺素受体是否是肥胖症和/或 2 型糖尿病治疗的有效靶点?
Biomolecules. 2023 Nov 28;13(12):1714. doi: 10.3390/biom13121714.
3
2-Phenethylamines in Medicinal Chemistry: A Review.2-苯乙胺类化合物在药物化学中的研究进展:综述
Molecules. 2023 Jan 14;28(2):855. doi: 10.3390/molecules28020855.
4
The mechanism exploration of the non-colonic toxicity and obesity inhibition of food-grade κ-carrageenan by transcriptome.通过转录组学对食品级κ-卡拉胶的非结肠毒性和肥胖抑制作用机制的探索
Food Sci Nutr. 2021 Sep 28;9(11):6232-6244. doi: 10.1002/fsn3.2581. eCollection 2021 Nov.
5
Everything You Always Wanted to Know about β-AR * (* But Were Afraid to Ask).关于β-AR 的一切,你一直想知道(*但又不敢问)。
Cells. 2019 Apr 16;8(4):357. doi: 10.3390/cells8040357.
6
Agonist-induced desensitisation of β -adrenoceptors: Where, when, and how?激动剂诱导的β-肾上腺素受体脱敏:在何处、何时以及如何发生?
Br J Pharmacol. 2019 Jul;176(14):2539-2558. doi: 10.1111/bph.14633. Epub 2019 Apr 7.
7
β-Adrenergic receptor-dependent modulation of the medium afterhyperpolarization in rat hippocampal CA1 pyramidal neurons.β-肾上腺素受体依赖性调制大鼠海马 CA1 锥体神经元中的中后超极化。
J Neurophysiol. 2019 Mar 1;121(3):773-784. doi: 10.1152/jn.00334.2018. Epub 2019 Jan 9.
8
Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles.基于 3D-QSAR CoMFA/CoMSIA 的构效关系及人β3-肾上腺素能受体选择性芳氧基丙醇胺激动剂的设计及其抗肥胖和抗糖尿病特性。
Molecules. 2018 May 16;23(5):1191. doi: 10.3390/molecules23051191.
9
2D-QSAR and 3D-QSAR/CoMSIA Studies on a Series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-Phenylethan-1-ol with Human β₃-Adrenergic Activity.一系列具有人β₃-肾上腺素能活性的(R)-2-((2-(1H-吲哚-2-基)乙基)氨基)-1-苯基乙醇的二维定量构效关系和三维定量构效关系/比较分子相似性指数分析研究
Molecules. 2017 Mar 5;22(3):404. doi: 10.3390/molecules22030404.
10
Classification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and Obesity.用于棕色脂肪组织激活的治疗性和实验性药物分类:糖尿病和肥胖症的潜在治疗策略
Curr Diabetes Rev. 2016;12(4):414-428. doi: 10.2174/1573399812666160517115450.

本文引用的文献

1
THE ADRENERGIC RECEPTIVE MECHANISM OF THE RAT UTERUS.大鼠子宫的肾上腺素能受体机制
J Pharmacol Exp Ther. 1963 Nov;142:178-84.
2
Some quantitative uses of drug antagonists.药物拮抗剂的一些定量应用。
Br J Pharmacol Chemother. 1959 Mar;14(1):48-58. doi: 10.1111/j.1476-5381.1959.tb00928.x.
3
Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs.棕色脂肪细胞上的非典型β-肾上腺素能受体作为抗肥胖药物的靶点。
Nature. 1984;309(5964):163-5. doi: 10.1038/309163a0.
4
beta-Adrenoceptor activation induces prostaglandin E2 generation in guinea-pig trachea.β-肾上腺素能受体激活可诱导豚鼠气管中前列腺素E2的生成。
Eur J Pharmacol. 1981 Jun 19;72(2-3):227-31. doi: 10.1016/0014-2999(81)90277-6.
5
Effect of dopamine on dog distal colon in-vitro.多巴胺对犬离体远端结肠的作用。
J Pharm Pharmacol. 1984 Jul;36(7):454-7. doi: 10.1111/j.2042-7158.1984.tb04424.x.
6
The rat lipolytic beta-adrenoceptor: studies using novel beta-adrenoceptor agonists.大鼠脂解β-肾上腺素能受体:使用新型β-肾上腺素能受体激动剂的研究
Eur J Pharmacol. 1984 May 4;100(3-4):309-19. doi: 10.1016/0014-2999(84)90007-4.
7
A model for the interaction of competitive antagonists with two receptor-subtypes characterized by a Schild-plot with apparent slope unity. Agonist-dependent enantiomeric affinity ratios for bupranolol in tracheae but not in right atria of guinea pigs.一种竞争性拮抗剂与两种受体亚型相互作用的模型,其特征为希尔德图的表观斜率为1。豚鼠气管中但非右心房中布普萘洛尔的激动剂依赖性对映体亲和力比值。
Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):111-20. doi: 10.1007/BF00512383.
8
Theoretical and practical problems with the assessment of intrinsic efficacy of agonists: efficacy of reputed beta-1 selective adrenoceptor agonists for beta-2 adrenoceptors.激动剂内在效能评估的理论与实践问题:公认的β-1选择性肾上腺素能受体激动剂对β-2肾上腺素能受体的效能
J Pharmacol Exp Ther. 1982 Nov;223(2):416-23.
9
Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues.ICI 118,551是一种强效、高度β2选择性肾上腺素能受体拮抗剂,可用于鉴定组织中的β肾上腺素能受体群体的证据。
Life Sci. 1980 Aug 25;27(8):671-7. doi: 10.1016/0024-3205(80)90008-9.
10
The classification of drugs and drug receptors in isolated tissues.离体组织中药物及药物受体的分类
Pharmacol Rev. 1984 Sep;36(3):165-222.